Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: Five year prospective study

British Medical Journal

Volumn 328, Issue 7439, 2004, Pages 545-548

  Plowe, Christopher V ^a   Kublin, James G ^a   Dzinjalamala, Fraction K ^b   Kamwendo, Deborah S ^b   Mukadam, Rabia A G ^b   Chimpeni, Phillips ^b   Molyneux, Malcolm E ^c   Taylor, Terrie E ^d  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; HALOFANTRINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEALTH CENTER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALAWI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG EVALUATION; DRUG RESISTANCE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALAWI; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 1542283603     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993;167:932-7.
2. Nzila AM, Nduati E, Mberu EK, Hopkins SC, Monks SA, Winstanley PA, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000;181:2023-8.
3. Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, et al. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 2001;64:242-6.
4. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990;87:3018-22.
5. Triglia T, Menting JGT, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997;94:13944-9.
6. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002;185:380-8.
7. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria following cessation of chloroquine use in Malawi. J Infect Dis 2003;187:1870-5.
8. Plowe CV, Kublin JG, Doumbo OK. P. falcipanim dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resist Update 1998;1:389-96.
9. Cortese JF, Plowe CV. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutants expressed in yeast. Mol Biochem Parasitol 1998;94:205-14.
10. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997;94:1124-9.